Amgen's IMDELLTRA Gets Full FDA Approval For Extensive Stage Small Cell Lung Cancer

Amgen said the FDA has granted full approval to IMDELLTRA (tarlatamab-dlle) for adult patients with extensive-stage small cell lung cancer (ES-SCLC) who progressed on or after platinum-based chemotherapy, converting its prior accelerated approval based on data from the global Phase 3 DeLLphi-304 trial. DeLLphi-304 met its primary endpoint, showing a 40% reduction in the risk of death and more than a five-month median overall survival benefit versus standard-of-care chemotherapy, and the NCCN recently updated its guidelines to list tarlatamab as the only Category 1 preferred treatment option in this setting. The regulatory and guideline moves effectively establish tarlatamab as the preferred therapy for post-platinum ES-SCLC, reinforcing Amgen’s positioning in this indication.

Analysis

Amgen announced the FDA has converted IMDELLTRA (tarlatamab-dlle) from accelerated to full approval for adult patients with extensive-stage small cell lung cancer (ES-SCLC) who progressed on or after platinum-based chemotherapy, citing results from the global Phase 3 DeLLphi-304 trial. DeLLphi-304 met its primary endpoint, showing a 40% reduction in the risk of death and more than a five-month improvement in median overall survival versus standard-of-care chemotherapy, which directly supports the regulatory upgrade.

The National Comprehensive Cancer Network updated its guidelines to list tarlatamab as the only Category 1 preferred treatment option in this post-platinum ES-SCLC setting, a designation that typically facilitates formulary placement and payer acceptance. Full FDA approval plus a Category 1 recommendation materially reduces regulatory uncertainty and strengthens Amgen’s commercial positioning in a line of therapy where the trial demonstrated a clear survival benefit.

Near-term commercial upside depends on real-world uptake, pricing and reimbursement decisions, and how broadly prescribers adopt the new standard; the label remains for patients post-platinum, so the addressable population is constrained by that indication. Investors should monitor initial sales, payer coverage announcements, and any emerging safety or supply issues as the primary determinants of whether the approval drives meaningful revenue growth for AMGN.

Key Decisions for Investors

• Consider increasing exposure to AMGN given full FDA approval and NCCN Category 1 designation, which de-risks commercialization and supports potential near-term revenue upside in post-platinum ES-SCLC, while scaling into confirmed uptake data
• Monitor quarterly sales, payer coverage/formulary decisions, and real-world safety/tolerability closely and be prepared to hedge or trim positions if uptake or reimbursement falls short of expectations
• For shorter-term traders, wait for initial market-share and reimbursement readouts before adding size; for longer-term investors, treat this as a positive catalyst within Amgen's oncology franchise